Bjørn-Eivind Kirsebom
Job description
Conducting research, lecturing and supervision of doctoral candiates in clinical neuropsychology/neurology with emphasis on neurodegenerative diseases in old age (Primarily Alzheimer's Disease).
PI Dementia Disease Initiation (DDI) Tromsø.
Ingvild Vøllo Eliassen,
Bjørn-Eivind Kirsebom,
Knut Waterloo,
Ragnhild Eide Skogseth,
Gøril Rolfseng Grøntvedt,
Mathilde Suhr Hemminghyth
et al.:
Pathological biomarkers for Alzheimer’s disease in cognitively unimpaired individuals are not associated with cognitive decline at two-year follow-up
Burak Arslan,
Ulf Andreasson,
Elzbieta Rembeza,
Markus Axelsson,
Lenka Novakova,
Bjørn-Eivind Kirsebom
et al.:
Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
Bjørn-Eivind Kirsebom,
Johanna Nilsson,
Ellen Vromen,
Peter Mikael Arnesen,
Atle Bjørnerud,
Ann Brinkmalm
et al.:
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways
Julie E Oomens,
Stephanie JB Vos,
Nancy N Maserejian,
Mercè Boada,
Mira Didic,
Sebastiaan Engelborghs
et al.:
Associations of lifestyle factors with amyloid pathology in persons without dementia
Beatriz E. Padrela,
Sandra Raquel Ramos Teceläo,
Bjørn-Eivind Kirsebom,
Oliver Marcel Geier,
Mario Tranfa,
Federico Masserini
et al.:
Blood-brain barrier water exchange in relation to amyloid, cognition and cerebrovascular burden
Fernando Gonzalez-Ortiz,
Jakub Vávra,
Emma Payne,
Bjørn-Eivind Kirsebom,
Ulrika Sjöbom,
Cristiano Santos
et al.:
The potential dual role of tau phosphorylation: Plasma phosphorylated-tau217 in newborns and Alzheimer's disease
Grit Richter,
Bjørn-Eivind Kirsebom,
Jonas Alexander Jarholm,
Lene Pålhaugen,
Berglind Gisladottir,
Dag Aarsland
et al.:
Comparison of CSF neurofilament light chain and total tau as neurodegeneration markers: Associations with synaptic markers and cognitive outcomes
Therese Händel Waggestad,
Bjørn-Eivind Seljelid Kirsebom,
Carsten Strobel,
Linda Gjøra,
Geir Selbæk,
Peter Wetterberg
et al.:
New regression-based norms for the Trail Making Test on Norwegian older adults: Understanding the effect of education
Anders Wimo,
Ron Handels,
Kaj Blennow,
Bjørn-Eivind Kirsebom,
Per Selnes,
Jaka Bon
et al.:
Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting
Fernando Gonzalez-Ortiz,
Bjørn-Eivind Kirsebom,
Yara Yakoub,
Julia Kristine Gundersen,
Lene Pålhaugen,
Knut Waterloo
et al.:
Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut Waterloo,
Santiago Timón-Reina
et al.:
Norwegian normative data for regression-based D-KEFS color-word interference test derived measures and comparison to conventional contrast measures
Stephanie Knudtzon,
Kaja Nordengen,
Lene Pålhaugen,
Berglind Gisladottir,
Jonas Alexander Jarholm,
Geir Bråthen
et al.:
Sexual dimorphisms in innate immune activation markers in predementia Alzheimer’s disease
Wietse A. Wiels,
Julie E. Oomens,
Sebastiaan Engelborghs,
Chris Baeken,
Christine A.F. Von Arnim,
Mercè Boada
et al.:
Depressive Symptoms and Amyloid Pathology
Bjørn-Eivind Kirsebom,
Fernando Gonzalez-Ortiz,
Sinthujah Vigneswaran,
Geir Bråthen,
Ragnhild Eide Skogseth,
Berglind Gisladottir
et al.:
Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity
Mathilde Suhr Hemminghyth,
Monica Haraldseid Breitve,
Luiza Chwiszczuk,
Berglind Gisladottir,
Erik Hessen,
Nikias Ioannis Siafarikas
et al.:
Demographically unadjusted cognitive test scores may enhance the validity of mild cognitive impairment as a dementia prodrome
Robin Ziyue Zhou,
Stefan Gaunitz,
Bjørn-Eivind Kirsebom,
Britt Lundin,
Marie Hellström,
Alenka Jejcic
et al.:
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer's disease
Mathilde Suhr Hemminghyth,
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling
et al.:
Cerebrospinal fluid neurofilament light chain mediates age-associated lower learning and memory in healthy adults
Mostafa Mehdipour Ghazi,
Per Selnes,
Santiago Timon Reina,
Sandra Raquel Ramos Teceläo,
Silvia Ingala,
Atle Bjørnerud
et al.:
Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts
Julia Kristine Gundersen,
Fernando Gonzalez-Ortiz,
Thomas Karikari,
Bjørn-Eivind Seljelid Kirsebom,
Katrin Mertes,
Henrik Zetterberg
et al.:
Neuronal plasma biomarkers in acute ischemic stroke
Anders Wimo,
Bjørn-Eivind Seljelid Kirsebom,
Santiago Timon Reina,
Ellen Vromen,
Per Selnes,
Jaka Bon
et al.:
Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project
Cecilia Magdalena Eriksson,
Bjørn-Eivind Seljelid Kirsebom,
Ragna Espenes,
Nikias Ioannis Siafarikas,
Knut Waterloo,
Arvid Rongve
et al.:
Depressive Symptoms Are Not Associated with Predementia Cerebrospinal Fluid Amyloid Pathology
Sofia Egebäck Arulf,
Robin Ziyue Zhou,
Bjørn-Eivind Seljelid Kirsebom,
Alenka Jejcic,
Tormod Fladby,
Bengt Winblad
et al.:
Bisecting N-Acetylglucosamine Correlates with Phospho-Tau181 in Subjective Cognitive Decline but not in Control Cases
Fernando Gonzalez-Ortiz,
Thomas K. Karikari,
Danielle Taylor-Te Vruchte,
Dawn Shepherd,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
et al.:
Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C
Fernando Gonzalez-Ortiz,
Bjørn-Eivind Seljelid Kirsebom,
José Contador,
Jordan E. Tanley,
Per Selnes,
Berglind Gisladottir
et al.:
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
Stephanie Knudtzon,
Kaja Nordengen,
Gøril Rolfseng Grøntvedt,
Jonas Alexander Jarholm,
Ingvild Vøllo Eliassen,
Per Selnes
et al.:
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer’s Disease
Giuseppe Mario Bentivenga,
Fernando Gonzalez-Ortiz,
Simone Baiardi,
Bjørn-Eivind Seljelid Kirsebom,
Andrea Mastrangelo,
Angela Mammana
et al.:
Clinical value of novel blood-based tau biomarkers in Creutzfeldt–Jakob disease
Kaja Nordengen,
Bjørn-Eivind Seljelid Kirsebom,
Grit Richter,
Lene Pålhaugen,
Berglind Gisladottir,
Nikias Ioannis Siafarikas
et al.:
Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease
Fredrik Öhman,
Marie Eckerström,
Erik Hessen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Ingrid Myrvoll Lorentzen
et al.:
Demographically adjusted Rey–Osterrieth Complex Figure Test norms in a Swedish and Norwegian cohort aged 49–77 years and comparison with North American norms
Johan Jacob Espenes,
Ingrid Myrvoll Lorentzen,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Santiago Timón
et al.:
Regression-based normative data for the D-KEFS Color-Word Interference Test in Norwegian adults ages 20–85
Therese Händel Waggestad,
Bjørn-Eivind Kirsebom,
Carsten Strobel,
Anders Wallin,
Marie Eckerström,
Tormod Fladby
et al.:
Improving validity of the trail making test with alphabet support
Jonas Alexander Jarholm,
Atle Bjørnerud,
Turi Olene Dalaker,
Mehdi Sadat Akhavi,
Bjørn-Eivind Kirsebom,
Lene Pålhaugen
et al.:
Medial Temporal Lobe Atrophy in Predementia Alzheimer's Disease: A Longitudinal Multi-Site Study Comparing Staging and A/T/N in a Clinical Research Cohort
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Erik Hessen,
Knut K Waterloo,
Arne Exner Nakling
et al.:
Investigating the relationship between allocentric spatial working memory and biomarker status in preclinical and prodromal Alzheimer’s disease
Klaus Thanke Aspli,
Jan Aaseth,
Trygve Holmøy,
Kaj Blennow,
Henrik Zetterberg,
Bjørn-Eivind Seljelid Kirsebom
et al.:
CSF, Blood, and MRI Biomarkers in Skogholt’s Disease—A Rare Neurodegenerative Disease in a Norwegian Kindred
Santiago Timón,
Mariano Rincón,
Rafael Martínez-Tomás,
Bjørn-Eivind Seljelid Kirsebom,
Tormod Fladby
:
A Knowledge Graph Framework for Dementia Research Data
Bjørn-Eivind Kirsebom,
Grit Richter,
Kaja Nordengen,
Dag Aarsland,
Geir Bråthen,
Betty M Tijms
et al.:
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients
Ingvild Vøllo Eliassen,
Bjørn-Eivind Kirsebom,
Tormod Fladby,
Knut Waterloo,
Sigrid Botne Sando,
Mathilde Suhr Hemminghyth
et al.:
Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease
Jacob Espenes,
Ingvild Vøllo Eliassen,
Fredrik Öhman,
Erik Hessen,
Knut K Waterloo,
Marie Eckerström
et al.:
Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49–79 and comparison with published norms
Miguel Germán Borda,
Daniel Ferreira,
Per Selnes,
Diego Alejandro Tovar-Rios,
Alberto Jaramillo-Jiménez,
Bjørn-Eivind Kirsebom
et al.:
Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness
Ingrid Myrvoll Lorentzen,
Johan Jacob Espenes,
Erik Hessen,
Knut Waterloo,
Geir Bråthen,
Santiago Timón
et al.:
Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
et al.:
Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
Johan Jacob Espenes,
Erik Hessen,
Ingvild Vøllo Eliassen,
Knut Waterloo,
Marie Eckerström,
Sigrid Botne Sando
et al.:
Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years
Ingvild Vøllo Eliassen,
Tormod Fladby,
Bjørn-Eivind Kirsebom,
Knut Waterloo,
Marie Eckerström,
Anders Wallin
et al.:
Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia
Fernando Gonzalez-Ortiz,
Michael K. Turton,
Johan Gobom,
Gunnar Brinkmalm,
Peter Harrison,
Anja Hviid Simonsen
et al.:
Novel MTBR-specific immunoassays MTBR-1 and MTBR-pTau262 for assessment of tau pathology in Alzheimer's disease
Trygve Holmøy,
Ingrid Marie Hardang,
Tormod Fladby,
Bjørn-Eivind Kirsebom,
Ragnhild Røysland
:
Nevrofilament lettkjede – en markør for nevronskade
Bjørn Blomberg,
Nikolai Norevik Myklebust,
Oddvar Oppegaard,
Camilla Tøndel,
Rebecca Jane Cox,
Arild Iversen
et al.:
Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial | Trials | Full Text
Mathilde Suhr Hemminghyth,
Monica Haraldseid Breitve,
Berglind Gisladottir,
Gøril Rolfseng Grøntvedt,
Arne Exner Nakling,
Tormod Fladby
et al.:
Cerebrospinal fluid neurofilament light chain mediates age-related decline in learning and memory in healthy adults
2023 ARKIV
Luiza Chwiszczuk,
Monica Haraldseid Breitve,
Bjørn-Eivind Kirsebom,
Per Selnes,
John Christian Jøraholmen Fløvig,
Anne Brita Knapskog
et al.:
The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial
Nikias Ioannis Siafarikas,
Bjørn-Eivind Kirsebom,
Deepak P. Srivastava,
Cecilia Magdalena Eriksson,
Eirik Auning,
Erik Hessen
et al.:
Author Correction: Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression (Scientific Reports, (2021), 11, 1, (20375), 10.1038/s41598-021-99794-9)
Johan Jacob Espenes,
Ingvild Vøllo Eliassen,
Tormod Fladby,
Marie Eckerström,
Wallin Anders,
Knut Waterloo
et al.:
Demographically adjusted test norms for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults
from 41 to 79 years
2020 ARKIV
Bjørn-Eivind Kirsebom
:
Hva vet vi om Alzheimers sykdom i dag, og finnes det en kur?
21. September 2020 ARKIV
The 50 latest publications is shown on this page. See all publications in NVA here →
Research interests
Clinical neuropsychology, regression-based norms, preclinical and prodromal Alzheimer's disease.
